This is an outdated version published on 23-12-2021. Read the most recent version.

Vol. 18 No. 4 (2021), Review papers

Vol. 18 No. 4 (2021)

The role of PET/CT in malignant melanoma diagnosis

Review papers

Published 23-12-2021

Paulina Kukla⁺⁻
Agata Karolina Pietrzak⁺⁻

Paulina Kukla

Katedra i Zakład Elektroradiologii Uniwersytetu Medycznego im. K.Marcinkowskiego w Poznaniu

https://orcid.org/0000-0002-5825-2193

Agata Karolina Pietrzak

Nuclear Medicine Dep.The Greater Poland Cancer Centre in Poznan, Poland

http://orcid.org/0000-0002-0476-5655

Versions

21-01-2022 (2)
23-12-2021 (1)

PDF (Polish)

Keywords

malignant melanoma
nuclear medicine
positron emission tomography

How to Cite

Kukla, Paulina, and Agata Karolina Pietrzak. 2021. “The Role of PET CT in Malignant Melanoma Diagnosis”. Letters in Oncology Science 18 (4): 86-91. https://journals.wco.pl/index.php/los/article/view/208.

Abstract

Malignant melanoma is the primary cause of morbidity among skin cancers patients. The positron emission tomography/computed tomography (PET/CT) study is one of the most used methods of imaging in oncology. It is also considered useful in malignant melanoma staging, restaging, and therapy planning.

PDF (Polish)

References

Tripp MK, Watson M, Balk SJ, Swetter SM, Gershenwald JE. State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. CA Cancer J Clin. 2016 Nov 12;66(6):460-480. doi: 10.3322/caac.21352. Epub 2016 May 27. PMID: 27232110; PMCID: PMC5124531.

De Vellis C, Pietrobono S, Stecca B. The Role of Glycosylation in Melanoma Progression. Cells. 2021 Aug 19 10(8):2136.

Scatena C, Murtas D, Tomei S. Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. Front Oncol. 2021 May 28;11:635488. doi: 10.3389/fonc.2021.635488. PMID: 34123788; PMCID: PMC8193952.

Spillane J, Henderson M, McArthur GA. Melanoma. PET/CT in Melanoma. 2017;1–8.

Markovic SN, Erickson LA, Rao RD, McWilliams RR, Kottschade LA, Creagan ET, i wsp. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clinic Proceedings. 2007 Mar;82(3):364–80.

M. Skórzewska, E. Stępak, Polkowski WP. Stan obecny oraz perspektywy leczenia czerniaka uogólnionego. Nowotwory Journal of Oncology. 2011;61(4):367–7.

Carson KJ, Hanna GG, Hounsell AR. Wykorzystanie 18F-FDG PET-CT do planowania leczenia napromienianiem. Nowotwory Journal of Oncology. 2011;61(4):326–6.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ; European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54. doi: 10.1007/s00259-014-2961-x. Epub 2014 Dec 2. PMID: 25452219; PMCID: PMC4315529.

Mikołajczyk A, Kwasigroch A, Grochowski M. System wspomagający diagnostykę czerniaka złośliwego przy pomocy metod przetwarzania obrazu i algorytmów inteligencji obliczeniowej. Zeszyty Naukowe Wydziału Elektrotechniki i Automatyki Politechniki Gdańskiej. 2016;Nr 51.

Henning JS, Dusza SW, Wang SQ, Marghoob AA, Rabinovitz HS, Polsky D, Kopf AW. The CASH (color, architecture, symmetry, and homogeneity) algorithm for dermoscopy. J Am Acad Dermatol. 2007 Jan;56(1):45-52. doi: 10.1016/j.jaad.2006.09.003. PMID: 17190620.

Zhou C, Louwman M, Wakkee M, van der Veldt A, Grünhagen D, Verhoef C, Mooyaart A, Nijsten T, Hollestein L. Primary Melanoma Characteristics of Metastatic Disease: A Nationwide Cancer Registry Study. Cancers (Basel). 2021 Sep 2;13(17):4431. doi: 10.3390/cancers13174431. PMID: 34503242; PMCID: PMC8431672..

Escribano-Pons MÁ, Segura-Sampedro JJ, Pineño-Flores C, Rodriguez Pino JC, González-Argenté FX, Morales-Soriano R. Abdominal metastatic melanoma invading transverse colon and stomach. Rev Esp Enferm Dig. 2021 Jul 28. doi: 10.17235/reed.2021.8052/2021. Epub ahead of print. PMID: 34315217.

Min KJ, Kim YS, Hong JH, Lee JK, Yang DS. Primary malignant melanoma of uterine cervix: a suggestion of new scheme of treatment combination. Chin J Cancer Res. 2014 Jun;26(3):351-4. doi: 10.3978/j.issn.1000-9604.2014.06.03. PMID: 25035664; PMCID: PMC4076715.

Dinnes J, Ferrante di Ruffano L, Takwoingi Y, Cheung ST, Nathan P, Matin RN, Chuchu N, Chan SA, Durack A, Bayliss SE, Gulati A, Patel L, Davenport C, Godfrey K, Subesinghe M, Traill Z, Deeks JJ, Williams HC; Cochrane Skin Cancer Diagnostic Test Accuracy Group. Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. Cochrane Database Syst Rev. 2019 Jul 1;7(7):CD012806. doi: 10.1002/14651858.CD012806.pub2. PMID: 31260100; PMCID: PMC6601698.

Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, Love C, Wenck S, Daggy J. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005 Aug 1;104(3):570-9. doi: 10.1002/cncr.21189. PMID: 15977211.

El-Shourbagy KH, Mashaly EM, Khodair SA, Houseni MM, Abou Khadrah RS. PET/CT in restaging, prognosis, and recurrence in patients with malignant melanoma. Egyptian Journal of Radiology and Nuclear Medicine. 2020 Aug;51(1).

Vensby PH, Schmidt G, Kjær A, Fischer BM. The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging. 2017 Dec 20;7(6):255-262. PMID: 29348980; PMCID: PMC5768920.

Kudura K, Dimitriou F, Mihic-Probst D, Muehlematter UJ, Kutzker T, Basler L, Förster R, Dummer R, Mangana J, Husmann L, Burger IA, Kreissl MC. Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients. Diagnostics (Basel). 2021 May 15;11(5):883. doi: 10.3390/diagnostics11050883. PMID: 34063555; PMCID: PMC8156636.

Kircher DA, Silvis MR, Cho JH, Holmen SL. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci. 2016 Sep 2;17(9):1468. doi: 10.3390/ijms17091468. PMID: 27598148; PMCID: PMC5037746..

Rutkowski P, Kiprian D, Dudzisz-Śledź M, Świtaj T, Michalik R, Spałek M, i wsp. Management of melanoma metastases in the brain. Nowotwory Journal of Oncology. 2019 Oct 31;69(3-4):86–96.

Medak A, Wojtowicz J, Pietrasz K, Cholewiński W, Pisarska B, Heydrych A, i wsp. Użyteczność badania 18F-FDG PET/CT w diagnostyce guzów pierwotnych

i przerzutów nowotworowych do mózgu. Letters in Oncology Science. 2020 Sep 22 17(3):1–7.

Parameswaran BK, Eddie Lau WF. Radiological Imaging in Melanoma. PET/CT in Melanoma. 2017;25–35

Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7. PMID: 21900389; PMCID: PMC3575079.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med. 2017 Sep;58(9):1421-1428. doi: 10.2967/jnumed.116.188839. Epub 2017 Mar 30. PMID: 28360208; PMCID: PMC5577627.

Perissinotti A, Rietbergen DD, Vidal-Sicart S, Riera AA, Olmos RAV. Melanoma & nuclear medicine: new insights & advances. Melanoma Manag. 2018 Jun 28;5(1):MMT06. doi: 10.2217/mmt-2017-0022. PMID: 30190932; PMCID: PMC6122522.

Ottaviano M, Giunta EF, Tortora M, Curvietto M, Attademo L, Bosso D, Cardalesi C, Rosanova M, De Placido P, Pietroluongo E, Riccio V, Mucci B, Parola S, Vitale MG, Palmieri G, Daniele B, Simeone E, On Behalf Of Scito Youth. BRAF Gene and Melanoma: Back to the Future. Int J Mol Sci. 2021 Mar 27;22(7):3474. doi: 10.3390/ijms22073474. PMID: 33801689; PMCID: PMC8037827.

Ascierto PA, Kirkwood JM, Grob JJ, Simeone E, Grimaldi AM, Maio M, Palmieri G, Testori A, Marincola FM, Mozzillo N. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 9;10:85. doi: 10.1186/1479-5876-10-85. PMID: 22554099; PMCID: PMC3391993.

Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW. BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. Mol Cancer Ther. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6. PMID: 25948295; PMCID: PMC4497841.

Le Goubey JB, Lasnon C, Nakouri I, Césaire L, de Pontville M, Nganoa C, Kottler D, Aide N. 18F-FDG PET/CT versus Diagnostic Contrast-Enhanced CT for Follow-Up of Stage IV Melanoma Patients Treated by Immune Checkpoint Inhibitors: Frequency and Management of Discordances over a 3-Year Period in a University Hospital. Diagnostics (Basel). 2021 Jul 1;11(7):1198. doi: 10.3390/diagnostics11071198. PMID: 34359281; PMCID: PMC8304093.

Pietrzak A, Marszałek A, Kunikowska J, Piotrowski T, Medak A, Pietrasz K, i wsp. Detection of clinically silent brain lesions in [18F]FDG PET/CT study in oncological patients: analysis of over 10,000 studies. Scientific Reports. 2021 Sep 14;11(1).

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

Downloads

Download data is not yet available.

Most read articles by the same author(s)

Agata Karolina Pietrzak, Michał Smoleń, Witold Cholewiński, Ocena przydatności badań opóźnionych 18F-FDG PET/CT w różnicowaniu zmian łagodnych i złośliwych , Letters in Oncology Science: Vol. 14 No. 3 (2017)
Agata Karolina Pietrzak, Wpływ pola elektromagnetycznego na rezystancję skóry ludzkiej – pomiary in vivo , Letters in Oncology Science: Vol. 14 No. 1 (2017)
Agata Karolina Pietrzak, Filip Nadolny, Witold Cholewiński, Początki medycyny nuklearnej w Europie. The development of Nuclear Medicine in Europe. , Letters in Oncology Science: Vol. 15 No. 1 (2018)
Agata Karolina Pietrzak, Karolina Kucnerowicz, Witold Cholewiński, Piotr Martenka, Erwin Strzesak, Qaly - measuring clinical effectiveness using EQ-5D-3L questionnaire , Letters in Oncology Science: Vol. 17 No. 1 (2020)
Adrianna Medak, BSc, Julia Wojtowicz, Katarzyna Pietrasz, MSc, Witold Cholewiński, MD PhD, prof., Beata Pisarska, MSc, Aleksandra Heydrych, MSc, Krzysztof Matuszewski, MSc, Hubert Szweda, MSc, Patrycja Mantaj, Radiation Protection Officer, Kamila Urbaniak, Radiation Protection Officer, Katarzyna Wiecheć, MSc, Agata K. Pietrzak, PhD, The utility of the 18F-FDG PET/CT in the primary and metastatic brain lesions diagnosis , Letters in Oncology Science: Vol. 17 No. 3 (2020)
Paulina Radzińska, Roksana Zając, Agata Karolina Pietrzak, Katarzyna Wiecheć, Jakub Żurawski, Witold Cholewiński, Obrazowanie radioizotopowe w onkologii pediatrycznej – przegląd metod , Letters in Oncology Science: Vol. 15 No. 4 (2018)
Roksana Zając, Paulina Radzińska, Agata Karolina Pietrzak, Katarzyna Wiecheć, Jakub Żurawski, Witold Cholewiński, Użyteczność metod radioizotopowych w leczeniu przerzutów nowotworowych do układu kostnego – przegląd metod , Letters in Oncology Science: Vol. 15 No. 4 (2018)
Aleksandra Feldgebel, Adrianna Medak, Witold Cholewiński, Agata Karolina Pietrzak, The utility of the 18F-FDG PET/CT study in the laryngeal cancer diagnosis , Letters in Oncology Science: Vol. 18 No. 3 (2021)
Agata Karolina Pietrzak, Piotr Martenka, MD, Erwin Strzesak, MD PhD, Katarzyna Pietrasz, MSc, Aleksandra Heydrych, MSc, Beata Pisarska, MSc, Karolina Kucnerowicz, MSc, Witold Cholewiński, Prof., The utility and limitations of the 18F-FDG PET/CT study in the oesophageal neoplasms diagnosis , Letters in Oncology Science: Vol. 17 No. 1 (2020)
Roksana Zając, Agata Karolina Pietrzak, Witold Cholewiński, The utility of the PET/CT method in Hodking’s lymphoma diagnosis , Letters in Oncology Science: Vol. 17 No. 3 (2020)